Genmab A/S (NASDAQ:GMAB) Receives an Average Analyst Rating of “Hold”
Genmab A/S Shares (NASDAQ: GMAB – Get a rating) received a consensus recommendation of “Hold” by the twelve brokerages that currently cover the stock, reports MarketBeat Ratings. One analyst rated the stock with a sell rating, seven gave the company a hold rating and two gave the company a buy rating. The average 1-year price target among brokerages that have reported on the stock in the past year is $547.62.
Several equity analysts have recently weighed in on GMAB shares. TheStreet upgraded Genmab A/S shares from a “c+” rating to a “b” rating in a Wednesday, August 31 research report. SVB Leerink raised its price target on Genmab A/S shares from $30.00 to $31.00 and gave the company a “market performance” rating in a research report Thursday, August 11. Morgan Stanley raised its price target on Genmab A/S shares from $29.00 to $31.00 and gave the company an “underweight” rating in a research report on Monday, August 15. HC Wainwright raised its price target on Genmab A/S shares from $49.00 to $51.00 and gave the company a “buy” rating in a Monday, August 22 research report. Finally, BMO Capital Markets began covering Genmab A/S shares in a research note on Thursday, June 23. They issued a “market performance” rating and a price target of $34.73 on the stock.
Genmab A/S trades up 0.1%
GMAB shares opened at $36.46 on Friday. Genmab A/S has a 12-month low of $26.19 and a 12-month high of $47.28. The company has a fifty-day simple moving average of $35.65 and a 200-day simple moving average of $33.88. The stock has a market capitalization of $23.99 billion, a price/earnings ratio of 40.51, a PEG ratio of 1.36 and a beta of 0.85.
Genmab A/S (NASDAQ: GMAB – Get a rating) last released its quarterly results on Wednesday, August 10. The company reported earnings per share (EPS) of $0.41 for the quarter, beating the consensus estimate of $0.21 by $0.20. Genmab A/S achieved a net margin of 38.42% and a return on equity of 17.12%. The company posted revenue of $452.86 million for the quarter, versus analyst estimates of $435.40 million. As a group, research analysts predict that Genmab A/S will post 1.02 earnings per share for the current fiscal year.
Institutional investors weigh in on Genmab A/S
A number of hedge funds have recently changed their positions in the stock. Private Capital Group LLC increased its stake in Genmab A/S by 14.1% in the 2nd quarter. Private Capital Group LLC now owns 2,677 shares of the company valued at $87,000 after buying 331 additional shares in the last quarter. Wetherby Asset Management Inc. increased its holdings in Genmab A/S by 2.6% in the fourth quarter. Wetherby Asset Management Inc. now owns 14,389 shares of the company valued at $569,000 after buying 358 additional shares in the last quarter. Private Advisor Group LLC increased its stake in Genmab A/S by 2.0% in the 2nd quarter. Private Advisor Group LLC now owns 20,522 shares of the company valued at $666,000 after buying 403 additional shares in the last quarter. Cim LLC increased its stake in Genmab A/S by 1.7% in the 1st quarter. Cim LLC now owns 27,994 shares of the company valued at $1,002,000 after purchasing an additional 465 shares in the last quarter. Finally, SG Americas Securities LLC increased its stake in Genmab A/S by 9.3% in the 1st quarter. SG Americas Securities LLC now owns 6,050 shares of the company valued at $219,000 after purchasing an additional 513 shares in the last quarter. 5.51% of the shares are currently held by institutional investors and hedge funds.
About Genmab A/S
Genmab A/S develops therapeutic antibodies for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Genmab A/S, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Genmab A/S was not on the list.
Although Genmab A/S currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here